Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tolcapone and Oxaliplatin in Relapsed/Refractory Neuroblastoma
NCT02630043Phase 1Terminated
- Start
- Dec 2015
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tolcapone in neuroblastoma. Primary endpoint: Number of Participants with Adverse Events as a Measure of Safety and Tolerability at 2 years. Started Dec 2015; status: terminated.
02
Drugs
tolcapone
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NCT02630043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02630043.